Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2000-06-29
2003-03-11
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S309000, C514S310000, C514S319000, C514S331000, C546S141000, C546S143000
Reexamination Certificate
active
06531464
ABSTRACT:
FIELD OF THE INVENTION
The invention relates to substituted phenanthridinones.
BACKGROUND OF THE INVENTION
Inflammation disorders, such as arthritis, colitis, and autoimmune diabetes typically manifest themselves as disorders distinct form those associated with reperfusion injury, e.g., stroke and heart attack, and can clinically manifest themselves as different entities. However, there can be common underlying mechanisms between these two types of disorders. In particular, inflammation and reperfusion injury can induce proinflammatory cytokine and chemokine synthesis. Induction of pro-inflammatorycytokines can, in turn, result in production of cytotoxic free radicals such as nitric oxide (NO) and superoxide. NO and superoxide can react to form peroxynitrite (ONOO
−
). Szabó et al., Shock 6:79-88, 1996.
The peroxynitrite-induced cell necrosis observed in inflammation and reperfusion injury involves, in significant part, the activation of the nuclear enzyme poly (ADP-ribose) synthetase (PARS). Activation of PARS is thought to be an important step in the cell-mediated death observed in inflammation and reperfusion injury. Szabó et al., Trends Pharmacol. Sci. 19: 287-98, 1998.
SUMMARY OF THE INVENTION
The invention is based in part on the discovery of novel substituted 6(5H)phenanthridinone derivatives and their unexpected effects in inhibiting inflammation, in treating reperfusion injuries, in reducing the severity of diabetes, in enhancing the function of a transplanted organ and for the treatment of symptoms associated with neurodegenerative diseases.
Accordingly, in one aspect the invention provides novel substituted 6(5H)phenanthridinone derivatives falling within Formula I, as set forth in the Detailed Description of the Invention, below.
Also provided is a method of treating inflammatory and reperfusion conditions in mammals by administering to a mammal in need of such treatment an effective amount of a compound according to Formula I.
In a further aspect, the invention also includes a method for the production of compounds of Formula I.
The substituted 6(5H)phenanthridinone compounds of the invention are potent, pharmaceutical compounds that can be used to treat a variety of conditions and diseases, typically those known to involve inflammatory mediator production and cell death.
The details of one or more embodiments of the invention are set forth in the accompanying description below. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are now described. Other features, objects, and advantages of the invention will be apparent from the description and from the claims. In the specification and the appended claims, the singular forms also include the plural unless the context clearly dictates otherwise. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. All patents and publications cited in this specification are incorporated by reference.
REFERENCES:
patent: 3291801 (1966-12-01), Montgomery
patent: 3932643 (1976-01-01), Gauthier
patent: 5519053 (1996-05-01), Kun et al.
patent: 5552267 (1996-09-01), Stern et al.
patent: 5583155 (1996-12-01), Kun et al.
patent: 5587384 (1996-12-01), Zhang et al.
patent: 5621104 (1997-04-01), Graham
patent: 5908861 (1999-06-01), Kun
patent: 6121278 (2000-09-01), Jackson et al.
patent: 6197785 (2001-03-01), Jackson et al.
patent: 6235748 (2001-05-01), Li et al.
patent: 6291425 (2001-09-01), Li et al.
patent: 6346536 (2002-02-01), Li et al.
patent: 6348475 (2002-02-01), Zhang et al.
patent: 6358975 (2002-03-01), Eliasson et al.
patent: 2002/0006917 (2002-01-01), Li et al.
patent: 2002/0019417 (2002-02-01), Zhang et al.
patent: 2002/0022636 (2002-02-01), Li et al.
patent: 2002/0028813 (2002-03-01), Jackson et al.
patent: 2002/0028815 (2002-03-01), Ator et al.
patent: 2002/0037904 (2002-03-01), Li et al.
patent: 0 638 309 (1995-02-01), None
patent: WO 99/08680 (1999-02-01), None
patent: WO 99/11622 (1999-03-01), None
patent: WO 99/11623 (1999-03-01), None
patent: WO 99/11624 (1999-03-01), None
patent: 9911624 (1999-03-01), None
patent: WO 99/11628 (1999-03-01), None
patent: WO 99/11644 (1999-03-01), None
patent: WO 99/11645 (1999-03-01), None
patent: WO 99/11649 (1999-03-01), None
patent: WO 99/36402 (1999-07-01), None
patent: WO 99/59973 (1999-11-01), None
patent: WO 99/59975 (1999-11-01), None
patent: WO 00/39070 (2000-07-01), None
patent: WO 00/39104 (2000-07-01), None
patent: WO 00/42040 (2000-07-01), None
patent: WO 01/21615 (2001-03-01), None
Cookson M.R. et al., “J. Neurochem.”,70/2.501-508(1998); Peroxynitrilew & Hydrogenoxide . . . role of ADP-rib.*
Weltin et al., “Int'l J. Rsd.Biol.”;72/6,685-692(1997);Effect fo 6(5H)-phenanthridinone-PARS.*
Ferrer, I. et al., Neuropathol.Appl.Neurobiol.; 26/5,424-433(200).*
Andrievskii , et al., Chem. Heterocycl. Compds. (English Transl.), 21, 924-931 (1985).
Banasik, et al., J. Biol. Chem., 267, 1569-1575 (1991).
Migachev & Terent'ev, Chem. Heterocycl. Compds. (English Transl.), 17, 394-397 (1981).
Nemeth, et al., Eur. J. Pharmacol, 339, 215-221 (1997).
Szabo, Shock, 6, 79-88 (1996)..
Szabo & Dawson, Trends Pharmacol. Sci., 19, 287-298 (1998).
Taylor & Strojny, J. Am. Chem. Soc., 78, 5104-5108 (1956).
Virag and Szabo, Br. J. Pharmacol., 126, 769-777 (1999).
Crowley, et al., Journal of Pharmacology, 259:78-85 (1991).
Weltin, et al., International Journal of Radiation Biology, 72:685-692 (1997).
Banisk M. and Ueda K., Mole. Cell. Biochem. 138:185-197 (1994).
Griffin et al., J. Med. Chem. 41:5247-5256 (1998).
White et al., J. Med. Chem. 43:4084-4097 (2000).
Jagtap Prakash
Salzman Andrew
Southan Garry
Szabo Csaba
Inotek Pharmaceutical Corporation
Patel Sudhaker B.
Pennie & Edmonds LLP
Raymond Richard L.
LandOfFree
Methods for the treatment of neurodegenerative disorders... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the treatment of neurodegenerative disorders..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the treatment of neurodegenerative disorders... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3085684